Healthcare and space stocks moved as investors weighed product revenue growth, guidance raises, backlog strength, and cash burn.
Stock Earnings Results
May 15, 2026
Table of Contents
May 14, 2026
Stocks saw company-level reactions on Thursday, with earnings results, product revenue growth, clinical updates, space-sector backlog growth, and medical diagnostics demand driving several notable moves.
Here are five stocks that reacted to major company events.
Move: +36.48%
Event: Earnings Beat and PEDMARK Revenue Growth
Shares of Fennec Pharmaceuticals rose 36.48% after the company reported first-quarter results above expectations, supported by strong PEDMARK sales and early benefits from its expanded field sales team.
Fennec is a specialty pharmaceutical company focused on PEDMARK, a treatment used to reduce the risk of cisplatin-induced hearing loss in pediatric patients.
The company reported EPS of $0.01, above estimates for a loss of $0.02, representing a 150.0% earnings surprise. Revenue came in at $15.11 million, above estimates of $13.94 million, with revenue growth of 72.6%.
Why It Moved:
Investors focused on PEDMARK demand, higher revenue, and stronger commercial execution. The company also said record PEDMARK demand in April and broader clinical interest across new patient populations could support continued growth.
Move: +5.73%
Event: Earnings Beat and Higher 2026 Guidance
Shares of CorMedix rose 5.73% after the company reported first-quarter results above expectations and raised its full-year revenue and adjusted EBITDA guidance.
CorMedix is a biopharmaceutical company focused on anti-infective products, including DefenCath for reducing catheter-related bloodstream infections in hemodialysis patients.
The company reported diluted EPS of $0.43, above estimates of $0.34, representing a 26.5% earnings surprise. Revenue came in at $127.43 million, above estimates of $109.85 million, with revenue growth of 226.1%.
Why It Moved:
The market focused on strong DefenCath utilization, contribution from the Melinta portfolio, and higher full-year guidance. CorMedix raised 2026 revenue guidance to $325 million to $345 million and adjusted EBITDA guidance to $115 million to $135 million.
Move: +2.35%
Event: Record Revenue, Positive Adjusted EBITDA, and Backlog Growth
Shares of Intuitive Machines rose 2.35% after the company reported record quarterly revenue, positive adjusted EBITDA, and a record quarter-end backlog of $1.1 billion.
Intuitive Machines is a space infrastructure and lunar services company supporting commercial, civil, and national security space missions.
The company reported a loss of $0.18 per share, wider than estimates for a loss of $0.07, representing a negative 157.1% earnings surprise. Revenue came in at $186.73 million, below estimates of $201.90 million, but still grew 198.7% year-over-year.
Why It Moved:
Investors looked past the earnings miss and focused on backlog growth, contract awards, and space infrastructure demand. The company ended the quarter with $1.1 billion in backlog and reported positive adjusted EBITDA of $2.7 million.
Move: 0.00%
Event: Q1 Results and EsoGuard Test Growth
Shares of Lucid Diagnostics were flat after the company reported first-quarter results with continued EsoGuard test volume, but a wider-than-expected loss and revenue below estimates.
Lucid Diagnostics is a commercial-stage cancer prevention diagnostics company focused on esophageal precancer and cancer detection through EsoGuard and EsoCheck.
The company reported a loss of $0.08 per share, wider than estimates for a loss of $0.06, representing a negative 33.3% earnings surprise. Revenue came in at $1.26 million, below estimates of $1.40 million, with revenue growth of 51.7%.
Why It Moved:
The flat move suggests investors balanced test-volume growth and balance sheet runway against continued losses and reimbursement uncertainty. Lucid processed 3,177 EsoGuard tests and ended the quarter with $45 million in pro forma cash.
Move: -7.02%
Event: Q1 Results Despite AUCATZYL Revenue Growth
Shares of Autolus Therapeutics fell 7.02% after the company reported first-quarter results showing AUCATZYL revenue growth, but continued losses and cash burn.
Autolus is a commercial-stage biopharmaceutical company developing programmed T cell therapies for cancer, autoimmune diseases, and neurological conditions.
The company reported AUCATZYL net product revenue of $26.2 million, up from $9.0 million in the prior-year period. The company also achieved positive gross margin for the ALL business.
Why It Moved:
Investors focused on continued losses and spending despite product revenue growth. Autolus reported a net loss of $71.6 million and announced a cost reduction initiative affecting about 13% of its workforce.
Today’s reactions show that healthcare and space-sector stocks are being judged on more than headline revenue growth.
Key themes included:
The strongest reaction came from Fennec, where the market rewarded revenue growth, EPS upside, and commercial momentum. The weakest reaction came from Autolus, where product growth was not enough to offset concerns about losses and operating expenses.
Today’s stock moves show that investors are rewarding companies with clearer paths to profitable growth.
Fennec and CorMedix rallied because product demand translated into stronger financial results. Intuitive Machines gained because backlog and adjusted EBITDA improved despite an earnings miss. Lucid Diagnostics remained flat as investors waited for reimbursement progress. Autolus fell because commercial revenue growth still came with heavy losses.
Platforms like LevelFields track earnings beats, activist investor stake, layoffs, earnings, strategic events, and dividends, helping investors identify which company events are actually driving short-term stock reactions.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better investor.
AI scans for events proven to impact stock prices, so you don't have to.
LEARN MORE